Eli Lilly and Company (LLY)vsMeta Platforms Inc. (META)
LLY
Eli Lilly and Company
$948.45
-2.72%
HEALTHCARE · Cap: $869.41B
META
Meta Platforms Inc.
$609.63
-1.16%
COMMUNICATION SERVICES · Cap: $1.57T
Smart Verdict
WallStSmart Research — data-driven comparison
Meta Platforms Inc. generates 198% more annual revenue ($214.96B vs $72.25B). LLY leads profitability with a 35.0% profit margin vs 32.8%. META appears more attractively valued with a PEG of 0.93. META earns a higher WallStSmart Score of 83/100 (A-).
LLY
Strong Buy78
out of 100
Grade: B+
META
Exceptional Buy83
out of 100
Grade: A-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+33.9%
Fair Value
$933.07
Current Price
$609.63
$323.44 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 108 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 33 in profit
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 40.6%
Revenue surging 33.1% year-over-year
Earnings expanding 62.4% YoY
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 27.2x book value
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : META
The strongest argument for META centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 32.8% and operating margin at 40.6%. Revenue growth of 33.1% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : META
The primary concerns for META are Piotroski F-Score.
Key Dynamics to Monitor
META carries more volatility with a beta of 1.24 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
META generates stronger free cash flow (13.2B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
META scores higher overall (83/100 vs 78/100), backed by strong 32.8% margins and 33.1% revenue growth. Both earn "Exceptional Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Meta Platforms Inc.
COMMUNICATION SERVICES · INTERNET CONTENT & INFORMATION · USA
Meta Platforms, Inc. develops products that enable people to connect and share with friends and family through mobile devices, PCs, virtual reality headsets, wearables and home devices around the world. The company is headquartered in Menlo Park, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?